Suppression of EGFR/PKC-δ/NF-κB Signaling Associated With Imipramine-Inhibited Progression of Non-Small Cell Lung Cancer

Abstract

Imipramine-triggered anti-NSCLC effects in both <i>in vitro</i> and <i>in vivo</i> model are at least partially attributed to its suppression of EGFR/PKC-δ/NF-κB pathway.